Labopharm signs first agreement for application of polymeric nano-delivery systems technology

    LAVAL, QC, June 16 /PRNewswire-FirstCall/ - Labopharm Inc. (TSX: DDS)
 today announced that it has entered into an agreement with Debiopharm S.A.
 under which Debiopharm has engaged Labopharm to conduct research on the
 potential oral delivery of a current intravenous cancer drug using Labopharm's
 proprietary polymeric nano- delivery systems technology (also referred to as
 micelles technology).
     "Following on the success of our patented Contramid(R) delivery
 technology for orally administered drugs, we are very pleased to have advanced
 our polymeric nano-delivery systems technology to the point of attracting our
 first partnership," said James R. Howard-Tripp, President and Chief Executive
 Officer, Labopharm Inc. "It has always been our long-term strategy to build a
 specialty pharmaceutical company based on integrated drug delivery platforms.
 Our core platform, Contramid(R), addresses very soluble to relatively
 insoluble compounds, which comprise the majority of drugs. With our polymeric
 nano-delivery system technology we can now address the delivery challenges of
 water insoluble compounds, as well as, potentially, proteins and peptides."
     Labopharm's polymeric nano-delivery systems are composed of proprietary,
 low cost, block co-polymers developed specifically for effective delivery of
 water insoluble compounds and poorly bio-available compounds, including highly
 toxic compounds, such as cancer drugs. Suitable for oral and parenteral
 administration, these high capacity, biocompatible and biodegradable carriers
 are designed to maximize drug efficacy and to avoid many of the dose-limiting
 side effects of conventional approaches. With applications in oncology,
 immunology and a variety of other therapeutic arenas, polymeric nano-delivery
 systems are expected to facilitate the delivery of both small molecules and
 emerging drug classes such as proteins, peptides and nucleic acids.
     About Debiopharm S.A.
     Debiopharm, founded in 1979 in Lausanne, Switzerland, focuses on
 evaluating compounds with promising in-vivo results in animals, to in-license,
 develop for global registration, and out-license to sales and marketing
 pharmaceutical partners. Debiopharm's major commercial successes to date are
 Eloxatin(R), one of Sanofi-Synthelabo's leading marketed products,
 Decapeptyl(R), the leading product of Ipsen in Southern Europe, and
 Trelstar(R), with combined sales estimated to be in excess of $1.8bn in 2004.
 Debiopharm is one of an established group of three complementary companies,
 Debiopharm, Debio R.P. and Debioclinic, with a successful track record in
 developing, registering and out-licensing innovative therapeutics. Debio R.P.
 is a leader in polymer-based controlled release technologies that allow
 certain drugs like proteins, peptides and anti-cancers to be delivered in
 customised, sustained-release formulation. From its FDA-inspected
 manufacturing facility in Martigny, Switzerland, Debio R.P. also conducts
 feasibility studies, formulation selection, optimisation, scale-up and cGMP
 manufacturing from clinical trial supplies to commercial scale. Debioclinic is
 a contract research organisation, specialised in oncology and dedicated to
 clinical development, providing regulatory, biometric and clinical support in
 line with cGCP. For more information on Debiopharm, visit the company's
 website at
     About Labopharm Inc.
     Labopharm Inc. (TSX:DDS) is an international specialty pharmaceutical
 company focused on the development of drugs incorporating the Company's
 proprietary advanced controlled-release technology, Contramid(R). Contramid(R)
 can be applied to a wide variety of drugs in solid oral dosage form, improving
 their oral administration and performance and is used to develop products that
 are either bio-equivalent to existing, branded products, or are new branded
 products. The Company's pipeline includes a combination of both in-house and
 partnered programs with products both in clinical trials and in preclinical
 development. Labopharm is also developing implantable mini-tablets based on
 Contramid(R) for local administration of drugs and novel polymeric nano-
 delivery systems for delivery of water-insoluble and poorly bio-available
 drugs. For more information, please visit
     This press release contains forward-looking statements, which reflect the
 Corporation's current expectations regarding future events. The forward-
 looking statements involve risks and uncertainties. Actual events could differ
 materially from those projected herein and depend on a number of factors,
 including the successful and timely completion of clinical studies, the
 uncertainties related to the regulatory process and the commercialization of
 the drug thereafter. Investors should consult the Corporation's ongoing
 quarterly filings and annual reports for additional information on risks and
 uncertainties relating to these forward-looking statements. The reader is
 cautioned not to rely on these forward-looking statements. The Corporation
 disclaims any obligation to update these forward-looking statements.

SOURCE Labopharm Inc.

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.


PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.